0 followers
Lowell Therapeutics is developing a breakthrough product and a company that makes a real difference in the lives of critically ill patients in the ICU. The phase 3 primary endpoint for their product, Niyad, will be met by proving it anti-coagulates blood.
Industries
Headquarters
Employees
Links